<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HA6FC087A46E443F1A7190961D45F856B" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 6897 IH: Synthetic Biology and Active Pharmaceutical Ingredients Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-12-22</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 6897</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20231222">December 22, 2023</action-date><action-desc><sponsor name-id="S001208">Ms. Slotkin</sponsor> (for herself and <cosponsor name-id="G000579">Mr. Gallagher</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HAS00">Committee on Armed Services</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To require the Secretary of Defense to establish a pilot program to evaluate novel pharmaceutical manufacturing technologies to reduce the reliance of the Department on foreign manufacturers for active pharmaceutical ingredients and key starting materials.</official-title></form><legis-body id="HCFFE8FCF30344C4C8901982BC350B091" style="OLC"><section id="HF6684F30140B4B91BE550F30B54673A5" section-type="section-one"><enum>1.</enum><header>Domestic synthetic biology pharmaceutical manufacturing pilot program</header><subsection id="H325E54C4B96F4016920AE9EB841B3C78"><enum>(a)</enum><header>Short title</header><text>This Act may be cited as the <quote><short-title>Synthetic Biology and Active Pharmaceutical Ingredients Act</short-title></quote>. </text></subsection><subsection id="H3688C152EFB846F4968B268FB7112C3C"><enum>(b)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than January 1, 2025, the Secretary of Defense shall establish a pilot program to evaluate the use of novel technologies using synthetic biology to expand domestic manufacturing of covered active pharmaceutical ingredients and covered key starting materials to reduce the reliance of the Department of Defense on foreign countries for such covered active pharmaceutical ingredients and covered key starting materials.</text></subsection><subsection id="HDD330C300B16448783C91999CE7C4651"><enum>(c)</enum><header>Sunset</header><text display-inline="yes-display-inline">The pilot program established under subsection (a) shall terminate on the date that is three years after the date of the enactment of this Act.</text></subsection><subsection id="H1366DBB5082A4072907288E15CE33513"><enum>(d)</enum><header>Definitions</header><paragraph id="HA1424451D53C4E499598781209A1048B"><enum>(1)</enum><header>Active pharmaceutical ingredient</header><text display-inline="yes-display-inline">The term <term>active pharmaceutical ingredient</term> has the meaning given such term in section 744A of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-41">21 U.S.C. 379j–41</external-xref>).</text></paragraph><paragraph id="HAB30A116778345E6BCC9090FF4F5F36D"><enum>(2)</enum><header>Covered active pharmaceutical ingredient</header><text display-inline="yes-display-inline">The term <term>covered active pharmaceutical ingredient</term> means an active pharmaceutical ingredient of which a sufficient quantity or quality is not available from domestic manufacturers to meet the needs of the Department and which the Secretary determines to be of strategic importance to the United States.</text></paragraph><paragraph id="HFB6E33CDB2AE4671964EB05677C6C83F"><enum>(3)</enum><header>Covered key starting material</header><text display-inline="yes-display-inline">The term <term>covered key starting material</term> means a key starting material of which a sufficient quantity or quality is not available from domestic manufacturers to meet the needs of the Department and which the Secretary determines to be of strategic importance to the United States.</text></paragraph><paragraph id="H22D7DA0269E74AD1B48E9F52CD71F2AA"><enum>(4)</enum><header>Key starting material</header><text display-inline="yes-display-inline">The term <term>key starting material</term> means any material that is—</text><subparagraph id="H03CD75A7B4C94513AB55986B748EBFC1"><enum>(A)</enum><text>used in the manufacture of an active pharmaceutical ingredient; and</text></subparagraph><subparagraph id="HC97D183245D5412E8D4C1A501E6A012A"><enum>(B)</enum><text display-inline="yes-display-inline">incorporated as an integral part of the active pharmaceutical ingredient.</text></subparagraph></paragraph></subsection></section></legis-body></bill> 

